Prime Medicine Unveils Strategically Focused Pipeline
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/14/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Citi Reiterates Buy Rating on Prime Medicine (PRME)
September 30, 2024 4:02 PM EDTCiti analyst Samantha Semenkow reiterated a Buy rating and $10.00 price target on Prime Medicine (NASDAQ: PRME).
The analyst comments "This morning, Prime announced a collaboration and licensing agreement with BMS focused on prime edited ex vivo T-cell therapies. The disclosure... More
